NY-PHILIP-MORRIS-INTL
17.8.2020 15:02:05 CEST | Business Wire | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced it will begin commercialization of KT&G’s smoke-free alternatives outside of South Korea. The announcement follows an agreement signed in January 2020 by PMI and KT&G, the leading South Korean tobacco and nicotine company.
PMI will launch KT&G’s lil SOLID device and its accompanying Fiit consumables in Russia. lil SOLID uses a pin-based tobacco heating system designed to provide four consecutive experiences without recharging. The lil SOLID device will be introduced by IQOS and will complement PMI’s existing portfolio of smoke-free alternatives in Russia, which includes the IQOS Tobacco Heating System. Other markets are being considered for subsequent commercialization of KT&G products.
“Our ambition is that all those who would otherwise continue to smoke switch as soon as possible to better alternatives and abandon cigarettes to the benefit of their health, public health and society at large,” said André Calantzopoulos, PMI’s Chief Executive Officer. “We are excited to enter into the next phase of our agreement with KT&G. The commercialization of KT&G’s products outside of South Korea will complement our already strong smoke-free portfolio, providing adult smokers with an even broader range of taste, price and technology options.”
The agreement between PMI and KT&G runs for an initial period of three years; it allows PMI to distribute current KT&G smoke-free products and their evolutions on an exclusive basis, and does not restrict PMI from distributing its own or third-party products. KT&G’s smoke-free products include tobacco heating systems (e.g., lil MINI and lil PLUS), hybrid technologies that combine heated tobacco and e-vapor technologies (e.g., lil HYBRID), and e-vapor products (e.g., lil VAPOR).
KT&G products to be distributed by PMI outside of South Korea, such as lil SOLID and Fiit , are subject to a careful assessment prior to commercialization to ensure they meet the applicable regulatory requirements in the markets where they are launched, as well as PMI’s high standards of scientific substantiation to confirm the absence of combustion and significant reductions in emissions of harmful chemicals compared to cigarettes.
This important step toward delivering a smoke-free future builds on other recent milestones related to PMI’s existing portfolio of smoke-free products. As of June 30, there were an estimated 15.4 million adult users of PMI’s IQOS Tobacco Heating System globally, of which 72 percent (over 11 million) have already stopped smoking and switched to IQOS.1 Additionally, on July 7, the U.S. Food and Drug Administration (FDA) authorized the marketing of the IQOS Tobacco Heating System as a modified risk tobacco product (MRTP), issuing an exposure modification order. In doing so, FDA recognized that the IQOS Tobacco Heating System is appropriate to promote the public health, and is expected to benefit the health of the population as a whole.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the U.S. under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2020, PMI estimates that approximately 11.2 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 57 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .
# # #
1 Source: Philip Morris International Inc. 2020 Second-Quarter Results—July 21, 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005305/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Expands its Partnership with Ducati Corse as Decades-Long Partnership Races Forward with Purpose23.4.2026 14:00:00 CEST | Press release
ZYN branding to be present at select MotoGP races in the 2026 season and beyond Philip Morris International1 (NYSE: PM) today announced an expanded partnership with Ducati Corse for the 2026 season and beyond. This next chapter introduces a major development: the ZYN brand of nicotine pouches—the number one nicotine pouch brand globally2—will feature on Ducati Corse MotoGP liveries at select races throughout the seasons. Just as Ducati pushes the limits of performance, ZYN represents PMI’s commitment to delivering innovation, offering a product that delivers exceptional quality while being thoughtfully designed. This partnership allows ZYN to connect with adult consumers in a space they’re passionate about—and to do so in a way that’s authentic, respectful, and dynamic. Philip Morris International’s relationship with Ducati Corse began in 2003—the year Ducati arrived in MotoGP—ushering in a bold new era of ambition. Since then, the collaboration has evolved alongside both organizations
Vitrealab and poLight ASA Partner to Tackle Coherence Artifacts in Laser-LCoS AR Displays23.4.2026 14:00:00 CEST | Press release
Vitrealab GmbH and poLight ASA (OSE: PLT) today announced a collaboration to advance laser illumination architectures for LCoS-based augmented reality (AR) displays, with a focus on mitigating coherence-related image artifacts while preserving system efficiency and compactness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423345474/en/ Vitrealab GmbH and poLight ASA (OSE: PLT) today announced a collaboration to advance laser illumination architectures for LCoS-based augmented reality (AR) displays, with a focus on mitigating coherence-related image artifacts while preserving system efficiency and compactness. Vitrealab’s Quantum Light Chip combined with poLight's TWedge® wobulation technology helps create a higher performing and more manufacturable AR system. Laser-based illumination offers clear system-level advantages for LCoS based AR light engines, including high optical efficiency due to intrinsic polarization, imp
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
